Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Health
By Teddy Rosenbluth from NYT Health https://ift.tt/2h0KB9E
via IFTTT your-feed-science, Falsification of Data, Clinical Trials, Regulation and Deregulation of Industry, Alzheimer's Disease, Decisions and Verdicts, Research, Securities and Commodities Violations Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda